Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)

D. O'Malley, M. Neffa, B. J. Monk, T. Melkadze, A. Kryzhanivska, I. V. Bulat, Tarek Meniawy, I. Bondarenko, W. I. Ortuzar Feliu, M. Ancukiewicz, I. Lugowska

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S727-S727
Number of pages1
JournalAnnals of Oncology
Publication statusPublished - 2021
EventCongress of the European-Society-for-Medical-Oncology (ESMO) -
Duration: 16 Sept 202121 Sept 2021

Cite this